Exelixis (EXEL) Non Operating Income (2011 - 2020)
Exelixis (EXEL) posted quarterly Non Operating Income of $7.7 million for Q1 2020, up 61.38% year-over-year from $4.8 million in Q1 2019, and up 9.18% quarter-over-quarter from $7.1 million in Q3 2019.
Analysis
Exelixis (EXEL) Non Operating Income (2011 - 2020) Analysis & Trends
Exelixis' Non Operating Income history runs 10 years deep, the most recent figure standing at $7.7 million for Q1 2020.
- In Q1 2020, Non Operating Income rose 61.38% year-over-year to $7.7 million; the TTM figure through Jan 2020 stood at $28.6 million (up 116.36% YoY), while the FY2020 annual figure was $28.6 million, up 116.36% from the prior year.
- Non Operating Income for Q1 2020 stood at $7.7 million, up from $7.1 million in the prior quarter.
- The five-year high for Non Operating Income was $7.8 million in Q2 2019, with the low at -$18.5 million in Q3 2016.
- The 5-year median for Non Operating Income is $2.3 million (2018), against an average of -$971125.0.
- The sharpest annual moves came in 2016 and 2018: Non Operating Income plunged 90.02% in 2016, then soared 220.78% in 2018.
- Exelixis' Non Operating Income stood at -$11.7 million in 2016, then surged by 112.66% to $1.5 million in 2017, then jumped by 220.78% to $4.8 million in 2018, then soared by 47.82% to $7.1 million in 2019, then increased by 9.18% to $7.7 million in 2020.
- Business Quant data shows EXEL's Non Operating Income at $7.7 million in Q1 2020, $7.1 million in Q3 2019, and $7.8 million in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jan 3, 2020 | 7.70 Mn |
| Sep 27, 2019 | 7.05 Mn |
| Jun 28, 2019 | 7.78 Mn |
| Mar 29, 2019 | 6.11 Mn |
| Dec 28, 2018 | 4.77 Mn |
| Sep 28, 2018 | 3.78 Mn |
| Jun 29, 2018 | 2.63 Mn |
| Mar 30, 2018 | 2.06 Mn |
| Dec 29, 2017 | 1.49 Mn |
| Sep 29, 2017 | 3.41 Mn |
| Jun 30, 2017 | -8.88 Mn |
| Mar 31, 2017 | -3.35 Mn |
| Dec 30, 2016 | -3.76 Mn |
| Sep 30, 2016 | -18.55 Mn |
| Jun 30, 2016 | -9.70 Mn |
| Mar 31, 2016 | -10.09 Mn |
| Sep 30, 2015 | -9.76 Mn |
| Jun 30, 2015 | -12.08 Mn |
| Mar 31, 2015 | -12.41 Mn |
| Dec 31, 2014 | -4.68 Mn |